On Dec. 4, 2020, Novo Nordisk announced that the FDA approved an updated label for Saxenda (liraglutide) injection 3 mg for use in the treatment of obesity in adolescents (12-17 years) with a body weight above 60 kg and an initial body mass index (BMI) corresponding to 30 kg/m2 or greater for adults, as an adjunct to reduced-calorie meals and increased physical activity.

Saxenda was approved in 2014 for chronic weight management in adults with a BMI =30 kg/m2, or =27 kg/m2 with at least one weight-related comorbidity, as an adjunct to a reduced calorie meal plan and increased physical activity.